Clinical trialNCT05358548RecruitingPhase 2Interventional

ATATcH Alternating Treatment Plans for Advanced Cancer

SponsorRutgers, The State University of New JerseyEnrollment150Head and Neck CancerLung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Missak Haigentz, MD
Rutgers Cancer Institute of New Jersey
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Trinitas Hospital and Comprehensive Cancer Center
Elizabeth, New Jersey, United States
Recruiting
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States
Recruiting
Rwjbarnabas Health - Jersey City
Jersey City, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center Southern Campus
Lakewood, New Jersey, United States
Recruiting
Rwjbarnabas Health - Saint Barnabas Medical Center
Livingston, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States
Recruiting
Rwj Barnabas Health - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
Not, yet, recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Recruiting
Rwjbarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States
Recruiting
Robert Wood Johnson Somerset Hospital
Somerville, New Jersey, United States
Recruiting
Rwjbarnabas Health - Community Medical Center
Toms River, New Jersey, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fluorouracil →Carboplatin →Paclitaxel →Pembrolizumab →Pemetrexed →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Apr 2022
Primary completion: 1 May 2027
Completion: 1 May 2028
Last update posted: 30 Apr 2026
Registered enrollment: 150
Registry id: NCT05358548

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.